Does Liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus?: ABCD Nationwide Liraglutide Audit RESULTS Table 1. Baseline characteristics categorised by baseline ALT

P Sen Gupta^1,2, KY Thong¹, M Cull¹, P Winocour³, REJ Ryder¹, on behalf of the ABCD nationwide liraglutide audit

¹City Hospital, Birmingham

²King’s College, London

³Queen Elizabeth II Hospital, Hertfordshire

Liraglutide is effective across a range of overweight and obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

Ryder REJ¹, Sen-Gupta P¹, Thong KY¹

¹City Hospital, Birmingham, UK

Liraglutide is Safe and Effective in Mild or Moderate Renal Impairment: the Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit

Thong KY¹, Walton C², Ryder REJ¹, ABCD Nationwide Liraglutide Audit Contributors

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

Insulin Necessity is Better than Diabetes Duration in Predicting Liraglutide Treatment Response: the Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit

Thong KY¹, Walton C², Ryder REJ¹, ABCD Nationwide Liraglutide Audit Contributors

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

K.Y. Thong¹, K. Darzy², M.L. Cull¹, A.P. Mills¹, R.E.J. Ryder¹, ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Diabetes, Birmingham, UK

²Queen Elizabeth II Hospital, Diabetes, Welwyn Garden City, UK

Factors associated with HbA1c and weight changes in the Association of British Clinical Diabetologists (ABCD) nationwide GLP-1 agonists audit

K.Y. Thong¹, R.E.J. Ryder¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Diabetes, Birmingham, UK

²Hull Royal Infirmary, Diabetes, Hull, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

Factors associated with HbA1c and weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y. Thong², ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, Hull Royal Infirmary, Hull, UK

²Diabetes, City Hospital, Birmingham, UK

Factors associated with HbA1c and Weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y. Thong², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, Hull Royal Infirmary, Hull, UK

²Diabetes, City Hospital, Birmingham, UK